AccessibilityHelpAbout Us
Alterity Therapeutics logo

Alterity Therapeutics(OTC) PRNAF

Market Cap$91.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2003)-98%
5 Year-62%
1 Year+167%
1 Month+14%
$0.40
+0.00%
+0.00Today
Alterity Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 0.402026-09-15
Alterity Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.402026-08-26
1 month+14.29%USD 0.352026-07-27
3 month+627.27%USD 0.062026-04-01
Year to date+28%USD 0.312025-11-25
1 year+166.67%USD 0.152025-06-16
3 year+81.82%USD 0.222023-08-31
5 year-62.26%USD 1.062021-09-16
Since inception-97.58%USD 16.502003-07-22

Alterity Therapeutics Financials at a Glance

Market Cap

$91.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$3.52M

Net Income (TTM)

-A$33.04M

EPS (TTM)

-$0.08

P/E Ratio

-5.31

Dividend

$0.00

Beta (Volatility)

0.00 (Low)

Price

$0.40

Volume

6

Open

$0.40

Previous Close

$0.40

Daily Range

$0.40 - $0.40

52-Week Range

$0.00 - $0.55

Estimated Earnings Date

Mar 4, 2027

PRNAF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alterity Therapeutics

Alterity Therapeutics Limited is a biotechnology company focused on the research and development of treatments for Parkinsonian and neurodegenerative disorders, including Multiple System Atrophy (MSA) and Parkinson's disease. The company is advancing its lead drug candidate, ATH434, which has completed Phase II clinical trials for Parkinson's disease and is also developing additional formulations for MSA.

Products and Services
  • ATH434: A small molecule drug candidate for Parkinson's disease
  • ATH434-201: Phase II clinical trial for early-stage MSA treatment
  • Drug discovery platform generating patentable compounds for neurological diseases
Growth Outlook
  • Strong pipeline with multiple Phase II trials underway for ATH434
  • Significant market potential in treating neurodegenerative disorders
  • Recent advancements in drug development may enhance investor interest
Financial Highlights
  • Cash and cash equivalents of approximately $37.27 million as of June 30, 2026
  • Trailing twelve months (TTM) cash ratio of 11.82 indicates strong liquidity
  • Operating expenses for Q4 2026 totaled approximately $15.38 million
Alterity Therapeutics Limited is positioned in a critical sector of healthcare, focusing on diseases that significantly impact quality of life. The company's commitment to developing innovative treatments for neurodegenerative disorders is underscored by its ongoing clinical trials and research initiatives. With a robust cash position and a strategic focus on advancing its drug candidates, Alterity Therapeutics presents a compelling opportunity for investors interested in the biotechnology sector. The potential for growth in this market, combined with the company's innovative approach, may attract attention from stakeholders looking for promising investment avenues.
AI Generated • Sep 17, 2026

Industry

Biotechnology

Sector

Health Care

Employees

11

CEO

David A. Stamler, MD

Website

www.alteritytherapeutics.com

Headquarters

Melbourne, VIC 3000, AU

PRNAF Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-48.25%

Return on Capital

-66.22%

Return on Assets

-50.85%

Earnings Yield

-18.83%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$91.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

229.15M

Volume

6

Avg. Volume

164.95

Financials (TTM)

Gross Profit

A$3.31M

Operating Income

-A$39.42M

EBITDA

-A$39.42M

Operating Cash Flow

-A$33.22M

Capital Expenditure

A$22.50M

Free Cash Flow

-A$12.14M

Cash & ST Invst.

A$37.27M

Total Debt

A$193.19K

Alterity Therapeutics Performance Analysis

Alterity Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Alterity Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-24.2%
Q42025-06-3019.3%
Q22025-12-31-100.0%
Q42026-06-30N/A
Alterity Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.19-1.2%
20242024-06-30AUD -0.17-10.3%
20252025-06-30AUD -0.06-64.2%
20262026-06-30AUD -0.0822.4%
Alterity Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3166.7%
Q42025-06-3078.6%
Q22025-12-31-233.3%
Q42026-06-30-26.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$57.56K

-102.9%

Gross Margin

0.00%

N/A

Market Cap

$91.66MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$8.33M

N/A

Employees

11

N/A

Net Income

-A$13.77M

+45.4%

EBITDA

-A$15.34M

-18.3%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$37.27M

+194.8%

Total Debt

A$193.19K

+21.5%

Accounts Receivable

A$7.69M

+91.3%

Inventory

A$0.00

N/A

Long Term Debt

A$138.10K

+166.0%

Short Term Debt

A$55.10K

-48.6%

Return on Assets

-50.85%

N/A

Return on Invested Capital

-66.30%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$11.89M

-46.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INOInovio Pharmaceuticals, Inc.
$1.24+2.48%
CRDFCardiff Oncology, Inc.
$1.39+6.92%
LVCLFAlgorae Pharmaceuticals Limited
$0.00-63.35%
SRBCFSirona Biochem Corp.
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About PRNAF

What is the current price of Alterity Therapeutics?

Alterity Therapeutics is trading at $0.40 per share.

What is the 52-week range for Alterity Therapeutics?

Over the past 52 weeks, Alterity Therapeutics has traded between $0.00 and $0.55.

How much debt does Alterity Therapeutics have?

As of the most recent reporting period, Alterity Therapeutics reported total debt of A$134.03K.

How much cash does Alterity Therapeutics have on hand?

Alterity Therapeutics reported A$25.85M in cash and cash equivalents in its most recent financial results.

What is Alterity Therapeutics’s dividend yield?

Alterity Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services